Brief: Atara Biotherapeutics To Close Global Tab-Cel® Partnership With Pierre Fabre Laboratories
Dec 20 (Reuters) - Atara Biotherapeutics Inc ATRA.O :
* ATARA BIOTHERAPEUTICS ANNOUNCES CLOSING OF EXPANDED GLOBAL
TAB-CEL® PARTNERSHIP WITH PIERRE FABRE LABORATORIES
* ATARA BIOTHERAPEUTICS INC - ATARA PLANS TO SUBMIT BLA TO
U.S.
FDA FOR TAB-CEL FOR TREATMENT OF POST-TRANSPLANT
LYMPHOPROLIFERATIVE DISEASE IN Q2 2024
Source text for Eikon: ID:nBw9s5B00a
Further company coverage: ATRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atara Biotherapeutics
See all newsBrief: Atara Biotherapeutics - May Offer Up To $79.27 Million In Common Stock As Of May 12, 2026 - SEC Filing
Atara Biotherapeutics Q1 revenue drops after prior-year one-time gain
Brief: Atara Biotherapeutics Q1 EPS USD -0.29
NASDAQ RESUMED AT 03:40 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:30 PM